Bloodstream Infection

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2022-05-19
Clinical Trial Update: Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection [Phase 3]
Phase 3 trial comparing ceftolozane-tazobactam to meropenem for ESBL/AmpC-producing Enterobacterales bacteremia was withdrawn.